Equities research analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report ($0.14) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings. Achillion Pharmaceuticals reported earnings per share of ($0.12) during the same quarter last year, which would indicate a negative year over year growth rate of 16.7%. The company is expected to issue its next earnings report on Wednesday, August 14th.
On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.59) per share for the current year. For the next financial year, analysts expect that the business will post earnings of ($0.67) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.14).
Achillion Pharmaceuticals stock traded up $0.02 during midday trading on Thursday, reaching $2.42. The stock had a trading volume of 529,377 shares, compared to its average volume of 1,497,810. The business has a 50-day moving average of $2.74. Achillion Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $3.98. The firm has a market cap of $327.40 million, a price-to-earnings ratio of -4.75 and a beta of 1.88.
A number of institutional investors and hedge funds have recently modified their holdings of ACHN. Metropolitan Life Insurance Co NY purchased a new stake in shares of Achillion Pharmaceuticals in the first quarter worth about $131,000. MetLife Investment Advisors LLC purchased a new stake in shares of Achillion Pharmaceuticals in the first quarter worth about $200,000. Mak Capital One LLC boosted its stake in shares of Achillion Pharmaceuticals by 33.5% in the first quarter. Mak Capital One LLC now owns 6,929,653 shares of the biopharmaceutical company’s stock worth $20,512,000 after buying an additional 1,738,053 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Achillion Pharmaceuticals by 22.1% in the first quarter. DekaBank Deutsche Girozentrale now owns 66,300 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 12,000 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Achillion Pharmaceuticals by 973.1% in the first quarter. Acadian Asset Management LLC now owns 278,573 shares of the biopharmaceutical company’s stock worth $825,000 after buying an additional 252,613 shares during the last quarter. 79.30% of the stock is owned by institutional investors and hedge funds.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Recommended Story: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.